Ginkgo Bioworks Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 10, 2023 and accepted by EDGAR at May 10, 2023, 20:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $80.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $162.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$215.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $82.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$205.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 1,916,637 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | −$90.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $19.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $1.21bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $1.33bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $2.42bn | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $191.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $809.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $1.61bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000950170-23-020535. Last ingested by Listed: Oct 29, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.